DIRS.INFO The most relevant business & tech news

The Summary Trump plans to tap Robert F. Kennedy Jr. to be his health and human services secretary. Kennedy has spread misinformation about vaccines, fluoride, raw milk and other topics. Kennedy has also referred to the Covid vaccine as “the deadliest vaccine ever made,” despite data showing it’s overwhelmingly safe. As many as 30 states allow raw milk to be sold, but the FDA regulates its sale across state lines. But Kennedy has cast doubt on those findings, claiming without evidence that the drugs were discredited because various groups stood to make money off Covid vaccines.

Persons: Trump, Robert F, Kennedy Jr, Kennedy, Donald Trump’s, ” Trump, Trump’s, Andrew Wakefield, “ I’m, ”, Howard Lutnick, glyphosate, hasn’t, haven’t, ivermectin, podcaster Joe Rogan, Elon Musk Organizations: NBC, Centers for Disease Control, FDA, National Institutes of Health, Medicare, Services, NBC News, Trump, CNN, CDC, European Union, International Agency for Research, Cancer, Environmental Protection Agency, American Academy of Pediatrics, National Cancer Institute

☆ These 3 UK stocks are on the march and set to soar by over 50%, RBC says
▼ + stars: | 2024-10-18 | by ( Ganesh Rao | ) www.cnbc.com time to read: +4 min

Three London stocks are on the march and are expected to rise by more than 50% over the next 12 months. TM17-GB 1Y line More recently, RBC said the company reported "a good set of results" in September. The company reported £80.6 million in total sales, missing revenue expectations of £81.5 million marginally. Wheeler also noted that the stock had "significant upside potential" after the company reported its first-half results on July 26. RBC analyst Charles Weston said the stock remains "materially undervalued" after the company reported its first half-year financial results.

Persons: Debbie Bestwick's, Steve Bell's, Frank Sagnier's, Ross Broadfoot, Broadfoot, Team17, RBC's Alexander Wheeler, Wheeler, Charles Weston, OXB Organizations: CNBC Pro, RBC Capital Markets, RBC, Drax, Oxford Biomedica, Oxford, University of Oxford Locations: London, England, Team17

☆ Insider Today: A shot to reverse aging
▼ + stars: | 2024-08-10 | by ( Joi-Marie Mckenzie | ) www.businessinsider.com time to read: +7 min

On the agenda:This story is available exclusively to Business Insider subscribers. AdvertisementVeronica Thatcher, who's worked at Costco for 18 years, told Business Insider she also spotted "Halloween- and harvest-themed decorative pillows" in the big-box store this month. According to eMarketer, Lowe's made Halloween merch available online on June 1 and it'll be available IRL on August 23. iStock; Rebecca Zisser/BIWealthy patient, healthy jointsIt's hard to slow down aging, but the wealthy are giving it their best shot, literally. More of this week's top reads:The Insider Today team: Jordan Parker Erb, editor, in New York.

Persons: —, I'm, Chelsea Jia Feng, you've, Veronica Thatcher, who's, Mike Booth, prepping, eMarketer, Lowe's, Taylor Rains, Insider's Taylor Rains, Beond, Rebecca Zisser, Bryan Johnson, — Johnson, Edward Berthelot, Burberry, Natalie Ammari, they've, Kit Harington, Oscar, Anthony Hopkins, Jordan Parker Erb, Dan DeFrancesco, Lisa Ryan, Amanda Yen Organizations: Service, Business, Retailers, Costco, CFVR, Home Depot, Burberry, US, HBO, Paramount, Showtime Locations: Alberta, Canada, Michaels, Italy, Maldives, Dubai, Bahamas, British, London, Nazi, New York, New York City

☆ Antiaging enthusiasts are getting $16,500 injections to make their knees young again
▼ + stars: | 2024-08-09 | by ( ) www.businessinsider.com time to read: +11 min

For now, here's what we know — and what we don't know — about stem-cell therapy for knees. Bryan Johnson flew to the Bahamas to get MSC stem cells injected into his knees, hips, and shoulders — for about $16,500 per joint. Plus, even Sampson warns that young donor stem cells should not be seen as a quick fix or a panacea. Done with proper medical oversight, some studies have found no adverse effects from stem-cell treatments for various conditions. Botched stem-cell treatments can cause infection, blindness, and excessive cell growth, which can trigger the formation of tumors.

Persons: —, Bryan Johnson, Johnson, hasn't, Josh DeAngelis, Rasul Chaudhry, Chaudhry, Steven Sampson, Chaundhry, Sampson, Peyton Manning, Patrick Smith, George Kittle, Hulk Hogan, TJ Dillashaw, Rafael Nadal, Jack Nicklaus, I've, it's, Paul Knoepfler, he's, It's, Mattias Bernow, we'll, Knoepfler Organizations: Service, Business, MSC, Oakland University, NFL, FDA, UFC, ESPN, CNN, UC Davis School of Medicine Locations: Bahamas, Panama

☆ John Cleese is a Miu Miu man
▼ + stars: | 2024-05-14 | by ( Leah Dolan | ) edition.cnn.com time to read: +3 min

CNN —A black crewneck, mid-wash jeans, white blazer and a distressed denim Miu Miu cap. Or is the senior a dedicated Miu Miu man? John Cleese's denim Miu Miu cap retails for $550. Originally billed as the spry, sometimes juvenile sibling to grown-up Prada, Miu Miu has not so much rebranded as redefined its vision of youth. Kristen Scott Thomas walked the runway for Miu Miu in September.

Persons: Miu, Sydney Sweeney, Emma Chamberlain — it’s, octogenarian John Cleese, Cleese —, Monty Python, “, —, Miu Miu, Cleese, Camilla Cleese, Robin Williams, Jean Paul, Gaultier, Issey Miyake, Alexander McQueen, John, Prada, spry, ‘, ’, Miuccia Prada, Kristen Scott Thomas, Emma Chamberlain, Ayo Edebiri, Emma Corrin, Qiu Huilan —, Chris Evans, Michael Palin, Terry Gilliam, ”, Evans Organizations: CNN, Paris Fashion, Virgin Radio Locations: British, Paris

☆ Generative A.I. Arrives in the Gene Editing World of CRISPR
▼ + stars: | 2024-04-22 | by ( Cade Metz | ) www.nytimes.com time to read: +1 min

Generative A.I. technologies can write poetry and computer programs or create images of teddy bears and videos of cartoon characters that look like something from a Hollywood movie. Now, new A.I. The company is expected to present the paper next month at the annual meeting of the American Society of Gene and Cell Therapy. Much as ChatGPT learns to generate language by analyzing Wikipedia articles, books and chat logs, Profluent’s technology creates new gene editors after analyzing enormous amounts of biological data, including microscopic mechanisms that scientists already use to edit human DNA.

Persons: ChatGPT Organizations: American Society of Gene, Cell Locations: Berkeley, Calif

But J&J's drug is walking away with a notable edge over its rival. They add more options to a growing arsenal of treatments that have helped improve outcomes for people with multiple myeloma. But the new approvals also give J&J's therapy, which was developed with Legend Biotech, a clear advantage over Bristol Myers's drug. J&J's drug has gradually gained ground over Abecma in the CAR-T market for multiple myeloma, even though it first entered the market a year later. With the new approval on Friday, Jefferies' Shi expects J&J's drug to win the majority of that market share.

Persons: Jonathan Raa, Johnson, Myers's, Bristol Myers, Jefferies, Kelly Shi, Shi, Carvykti, Cantor Fitzgerald, Rick Bienkowski, Kelsey Goodwin, Annika, annikakim.constantino@nbcuni.com Organizations: Nurphoto, Bristol Myers Squibb, Johnson, Food and Drug Administration, FDA, Legend Biotech, Bristol, New York Stock Exchange, NYSE, Reuters, Mount Sinai Hospital, Getty Locations: Bristol, U.S, EU, Japan, Mount Sinai, New York City

☆ Morgan Stanley thinks this little-known autoimmune biotech stock can surge more than 40%
▼ + stars: | 2024-03-04 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Newly public biotech Kyverna Therapeutics could be a blockbuster cell therapy developer for autoimmune disease, according to Morgan Stanley. The stock opened at $34.25, above the initial public offering price of $22 per share, and closed Friday at $27.75. Although the data from KYV-101 is limited, Ulz wrote that he's "highly encouraged given promising results across multiple indications, multiple sites, and in challenging patients." The analyst pointed out that cell therapies have "meaningfully improved" the treatment of B-cell cancers and that multiple therapies are currently approved, increasing the therapies' potential to treat autoimmune diseases. Ingenui-T is a next-generation process in preclinical development for manufacturing autologous anti-CD19 CAR T-cell therapy, and uses the same CAR construct as KYV-101, Kyverna said.

Persons: Morgan Stanley, Michael Ulz, Kyverna, Ulz Organizations: Therapeutics, Nasdaq, autoimmunity Locations: KYV, Kyverna

☆ Stocks making the biggest moves premarket: Super Micro Computer, Deckers Outdoor, Macy's and more
▼ + stars: | 2024-03-04 | by ( Samantha Subin | ) www.cnbc.com time to read: +3 min

Super Micro Computer , Deckers Outdoor — Shares of Super Micro Computer and Deckers Outdoor jumped 12% and 5%, respectively, after S & P Dow Jones Indices said Friday the two companies would be added to the S & P 500 later this month. They will replace Whirlpool and Zion Bancorp, which will move to the S & P MidCap 400 index as of the March 18 open. Macy's — Macy's stock skyrocketed nearly 17% after Arkhouse Management upped its buyout offer for the department store chain to $24 from $21 a share, or about $6.6 billion. Crypto stocks – Companies whose performance is tied to the price of bitcoin rose in premarket trading after the cryptocurrency touched another two-year high . Spirit AeroSystems , Boeing — Shares of the fuselage maker rose nearly 3%.

Persons: Dow, CleanSpark, AeroSystems, Lyft, Morgan Stanley, Li Auto, Piper Sandler, Brian Mullan, — CNBC's Lisa Han, Fred Imbert, Tanaya, Hakyung Kim, Jesse Pound, Michelle Fox Organizations: Micro Computer, Dow Jones, Whirlpool, Zion Bancorp, Arkhouse Management, Apple, European Commission, Marathon, Iris Energy, RBC, Boeing —, Boeing, Max, —, Citi, Li Auto, Li, Mobile

☆ Here are Monday's biggest analyst calls: Nvidia, Apple, Super Micro, Eli Lilly, Lyft, DoorDash, Disney & more
▼ + stars: | 2024-03-04 | by ( Michael Bloom | ) www.cnbc.com time to read: +9 min

UBS upgrades Norfolk Southern to buy from neutral UBS said it sees margin improvement for the railroad. Goldman Sachs initiates Super Micro as neutral Goldman said the stock is an "AI winner" but that valuation is full right now. UBS reiterates Eli Lilly as buy UBS raised its price target on the stock to $910 per share from $810. UBS reiterates Nvidia as buy UBS said it's sticking with its buy rating after a series of investor meetings with the company." Argus upgrades New York Times to buy from neutral Argus said it sees revenue growth for the newspaper company. "

Persons: Morgan Stanley, Disney, Piper Sandler, Piper, Guggenheim, Baird, SQSP, Goldman Sachs, Goldman, Bernstein, Tesla, underperform Bernstein, Eli Lilly, Wells, Melius, Citi downgrades Ferrari, Jefferies, Evercore, it's, Rosenblatt, Snowflake, Slootman's Organizations: BROS, Guggenheim, GSK, UBS, Norfolk Southern, Micro, JPMorgan, Nvidia, Kyverna Therapeutics, FLT, UDR, Conservative, America Health, RBC, Apple, Citi, Ferrari, Jefferies, BP, Barclays, Barclays downgrades, ISI, Toast Inc, Bank of America, Ball Corp, of America, Broadcom, New York Times Locations: Norfolk, China, New

☆ Stocks making the biggest moves midday: Macy's, Super Micro Computer, Lyft, DoorDash and more
▼ + stars: | 2024-03-04 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +3 min

Super Micro Computer , Deckers Outdoor — The technology firm and athletic footwear designer respectively popped 27% and nearly 3% after S & P Dow Jones Indices announced Friday that the two stocks would be added to the S & P 500 on March 18. Super Micro Computer and Deckers Outdoor will replace Zions Bancorpation and Whirlpool , which will move to the S & P MidCap 400 Index. Macy's — Shares skyrocketed 16% after Arkhouse Management said it and Brigade Capital Management have raised their offer for the department store . DoorDash — Shares jumped more than 5% after RBC upgraded the food delivery company to outperform from sector perform. Lyft — The ride-sharing platform added 6% after RBC upgraded the stock to an outperform rating from sector perform.

Persons: Dow, Zions, —, Lyft, Morgan Stanley, Li, Piper Sandler, Ford, CNBC's Michelle Fox, Alexander Harring, Hakyung Kim, Tanaya Macheel, Yun Li, Jesse Pound, Samantha Subin Organizations: Micro Computer, Dow Jones, Whirlpool, Arkhouse Management, Brigade Capital Management, Apple, European, Miners, Marathon Digital, Cipher Mining, Iris Energy, RBC, Kyverna Therapeutics, Wells, JPMorgan, Ferrari —, Citi, Li Auto, Dutch Bros, American Airlines —, Max Locations: Wells Fargo

☆ Here are Thursday's biggest analyst calls: Tesla, Apple, Boeing, IBM, Meta, Microsoft, Rivian, Amazon & more
▼ + stars: | 2024-01-25 | by ( Michael Bloom | ) www.cnbc.com time to read: +5 min

Goldman Sachs reiterates Apple as buy Goldman said it's standing by the tech giant heading into earnings on February 1. Bank of America reiterates Meta as buy Bank of America raised its price target on Meta to $425 per share from $405. Piper Sandler reiterates Microsoft as overweight Piper warned investors in a note on Thursday not to "sleep" on Microsoft Cloud. Bank of America downgrades Boeing to neutral from buy Bank of America said in its downgrade of the stock that it sees too much regulatory scrutiny. Bank of America upgrades Heico to buy from neutral Bank of America said investors should buy the dip in the aerospace and electronics aftermarket company. "

Persons: Needham, Rivian, Morgan Stanley, Tesla, Goldman Sachs, ServiceNow, Goldman, it's, TAL, BTIG, Jefferies, Wells, Piper Sandler, Piper, JPMorgan downgrades Hertz, JPM, Hertz Organizations: Bank of America, IBM, Revenue, Apple, JPMorgan, Tal, Bloom Energy, Gray Customers, Amazon, " Bank of America, Meta, DuPont, Microsoft, Deutsche Bank, Avis, Deutsche, Boeing, Alaska Airlines, of America Locations: ServiceNow, China, Bloom

☆ Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch
▼ + stars: | 2023-12-28 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +8 min

Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. "We expect this environment to continue but look forward to the prospect of lower interest rates in 2024." When that happens, Canaccord Genuity said to expect a "strong rally across the biotech sector rewarding innovative, but riskier assets." Analysts have said the rich price reflects the opportunity for ImmunoGen's Elahere cancer treatment , which has quickly established itself as the standard of care for types of ovarian cancer. 'Oversold and cheap' In a research note Friday, Jefferies analyst Michael Yee said "a significant short squeeze" was helping biotech stocks in the fourth quarter.

Persons: Dan Lyons, Janus Henderson, John Newman, Canaccord Genuity, Janus, Lyons, Bristol Myers Squibb, Karuna, AstraZeneca, Eli Lilly, AbbVie, Jonathan Miller, Miller, bode, Jonathan Krinsky, Krinsky, BTIG's, Jefferies, Michael Yee, Yee, NASH, Madrigal, we're, David Risinger, — CNBC's Michael Bloom Organizations: Drug, Federal, Bristol Myers, Karuna Therapeutics, CART, Bristol Myers Squibb, Cerevel Therapeutics, Securities and Exchange Commission, pharma, P Biotech, Nasdaq Biotech, Apogee Therapeutics, Madrigal Pharmaceuticals, Madrigal, resmetirom, Vertex Pharmaceuticals, Leerink Partners Locations: ImmunoGen

☆ US drug shortages are forcing ‘impossible choices’ for Americans, experts tell Senate committee
▼ + stars: | 2023-12-05 | by ( Jen Christensen | ) edition.cnn.com time to read: +7 min

Anderson Cancer Center in Houston, Dr. Jason Westin regularly witnesses the power of lifesaving cancer drugs. But because generic cancer drugs are often in shortage in the United States, he says, he and his patients have been put in a terrible position. Makers of generic drugs don’t have to share information about the supply chain, so buyers currently choose based only on price. Hernandez told the Senate committee that of the top 50 generic drugs paid for by Medicare Part D, 16 were marked up 1,000% or higher. Until there is some kind of legislation that addresses drug shortages, Wosińska and the other experts agreed, they will continue.

Persons: Jason Westin, ” Westin, that’s, they’d, Sen, Marsha Blackburn, Mike Crapo, Generics, ” Crapo, “, ”, Crapo, Inmaculada Hernandez, ” Hernandez, Dr, Marta E, it’s, ” Wosińska, Ron Wyden, ” Wyden, Hernandez, Sanjay Gupta Organizations: CNN, Anderson Cancer Center, US, Finance, Vanderbilt, Tennessee Republican, Food and Drug Administration, Westin, Skaggs School of Pharmacy, Pharmaceutical Sciences, University of California, Centers, Medicare, Medicaid Services, Brookings Institution, CNN Health Locations: M.D, Houston, United States, Nashville, Idaho, China, India, San Diego, Oregon, generics

☆ Here are Tuesday's biggest analyst calls: Netflix, Apple, IBM, Coinbase, Nike, Domino's, Meta, Charles Schwab and more
▼ + stars: | 2023-12-05 | by ( Michael Bloom | ) www.cnbc.com time to read: +9 min

Goldman Sachs reiterates Nike as buy After a transfer of analyst coverage, Goldman Sachs said it sees improving growth for Nike shares. UBS downgrades United Rentals to neutral from buy UBS said in its downgrade of the equipment rental company that it sees a more balanced risk/reward. UBS reiterates Apple as neutral UBS said its analysis of Apple's App Store shows revenue increasing. UBS reiterates Netflix as buy UBS said it's standing by its buy rating on Netflix shares after hosting the company at a conference. William Blair reiterates Charles Schwab as outperform William Blair named Schwab a top pick for 2024, noting it's well-positioned.

Persons: Raymond James, Piper Sandler downgrades Albemarle, Piper Sandler, it's, Goldman Sachs, Roth, Roth MKM, TD Cowen, Bernstein, Mizuho downgrades Prologis, Wells, Wells Fargo, Oppenheimer, Domino's, Elliott, Morgan Stanley, Meta, Needham, Coinbase, JPMorgan, Raymond James downgrades Lululemon, LULU, Strong, William Blair, Charles Schwab, Schwab Organizations: Crescent Energy, Energy Company, Eagle Ford, UW, Nike, Bank of America, UBS, Credit Suisse, Yale, HY, United Rentals, Apple, Semiconductors, JPMorgan, IBM, Consulting, Mizuho, Marriott, of America, Netflix, Management, Integra, Financial, ISI, Disney, BR, Cargo Therapeutics, Citi, Travere Therapeutics Locations: Houston, Uinta, Eagle, LTHM, 2024E, 2025E, Argentina, Boston, China, Mexican

☆ US FDA to delay decision on Bristol Myers-2seventy bio cancer therapy
▼ + stars: | 2023-11-20 | by ( ) www.reuters.com time to read: +2 min

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. The U.S. Food and Drug Administration (FDA) has not yet confirmed when the advisory panel would meet, they added. Shares of Bristol Myers Squibb fell more than 2% and those of 2seventy bio slid nearly 20% in early morning trade. The therapy was originally co-developed by bluebird bio (BLUE.O) but following its spin-off in 2021 became part of 2seventy's portfolio. Bristol Myers and 2seventy bio, however, have faced manufacturing constraints, and a month-long planned maintenance shutdown of one of Abecma's manufacturing facility in June had also negatively impacted sales.

Persons: Andrew Kelly, 2seventy bio's, Bristol Myers, Johnson, Biotech's, Khushi, Sriraj Kalluvila Organizations: Food and Drug Administration, FDA, REUTERS, Bristol Myers Squibb, U.S . Food, Drug Administration, Bristol, Johnson, Thomson Locations: White Oak , Maryland, U.S, Bengaluru

☆ This under-the-radar biopharma stock could more than double, Goldman Sachs says
▼ + stars: | 2023-11-20 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +1 min

Iovance Biotherapeutics ' star asset could propel its stock to new heights, according to Goldman Sachs. IOVA YTD mountain IOVA YTD chart Iovance specializes in developing autologous tumor-infiltrating lymphocyte, or TIL, therapies for solid tumor cancers using its lead asset lifileucel. As a catalyst, analyst Andrea Tan pointed to the upcoming approval of the company's first such treatment, which is slated to be reviewed by February 2024. "With accelerated approval, lifileucel would be the first cell therapy approved for solid tumors and IOVA is preparing for commercial launch," she wrote. The analyst added that lifileucel, a "best-in-class therapy," has the potential to become the standard of care in treating melanoma.

Persons: Iovance Biotherapeutics, Goldman Sachs, Andrea Tan, Tan, CNBC's Michael Bloom Locations: Friday's

☆ Goldman says this biotech could become a global cell therapy leader, has nearly 40% upside
▼ + stars: | 2023-11-06 | by ( Alex Harring | ) www.cnbc.com time to read: +1 min

Legend Biotech has a best-in-class product and could become a global leader in the cell and gene therapy space, according to Goldman Sachs. "We believe Legend has the potential to grow into a leading global cell therapy company," Chen said in a note to clients. Its leading therapy in the space is Carvykti, which he described as "best-in-class." In partnership with Johnson & Johnson , Carvykti is undergoing capacity expansion in the U.S. and European Union to meet demand. Legend stock rose 0.3% in Monday's session.

Persons: Goldman Sachs, Ziyi Chen, Chen, Johnson, Carvykti, — CNBC's Michael Bloom Organizations: Biotech, Johnson, Union Locations: U.S

☆ Activist Elliott makes inroads at Catalent to build value. Here’s what could happen next
▼ + stars: | 2023-09-16 | by ( Kenneth Squire | ) www.cnbc.com time to read: +7 min

This segment also handles the formulation, development and manufacturing for parenteral dose forms, including vials and prefilled syringes. Activist Commentary: Elliott is a very successful and astute activist investor, particularly in the technology sector. While as an activist Elliott will do whatever it feels is necessary to enhance shareholder value, in the past the firm has made significant use of the strategy of offering to acquire its portfolio companies as the best catalyst to enhance shareholder value. Like Catalent, Syneos is an outsourced pharma solutions company: It outsources R&D for pharmaceutical companies, whereas Catalent outsources manufacturing. If this does turn from a strategic review to an operational review, there is no guarantee that he keeps his job.

Persons: Catalent, there's, Elliott, Steven Barg, Frank D'Amelio, Stephanie Okey, Michelle Ryan, Johnson, Barg, Ryan, John Greisch, There's, Danaher, Alessandro Maselli, Ken Squire Organizations: Oral Technologies, Clinical, Pfizer, Rom Holdings, Bloomberg, Merck, Citrix Systems, Nielsen Holdings, Square, Veritas Capital, Syneos Health, 13D Locations: COOs, North America

☆ 2seventy bio to lay off 40% of workforce; CEO to step down
▼ + stars: | 2023-09-12 | by ( ) www.reuters.com time to read: +2 min

Nick Leschly, CEO of bluebird, speaks at the opening of Lonza Houston, the world’s largest dedicated cell and gene therapy facility, in Houston, Texas, U.S., April 10, 2018. REUTERS/Daniel Kramer Acquire Licensing RightsSept 12 (Reuters) - 2seventy bio (TSVT.O) said on Tuesday it plans to lay off about 40% of its workforce to lower costs and focus on the biotech firm's cancer cell therapy Abecma, lifting the company's shares more than 8% in premarket trade. The company added that CEO Nick Leschly will step down and transition to the role of chairman. Leschly was earlier the CEO of bluebird bio (BLUE.O) for 11 years, but changed role after the gene therapy maker's oncology portfolio was spun off from it as 2seventy. The company will now focus on another type of multiple myeloma patients, for which it expects approval from the U.S. Food and Drug Administration in mid-December.

Persons: Nick Leschly, Lonza, Daniel Kramer, Leschly, 2seventy, Abecma, Johnson, Bristol Myers, William Baird, Pratik Jain, Shounak Dasgupta, Maju Samuel Organizations: bluebird, REUTERS, Johnson, Legend Biotech, Bristol, Bristol Myers Squibb, U.S . Food, Drug Administration, Thomson Locations: Lonza Houston, Houston , Texas, U.S, Abecma, Bengaluru

☆ Gilead Sciences could jump nearly 30% as biopharma bounces back, says Bank of America
▼ + stars: | 2023-09-08 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

The biopharmaceutical sector is poised to bounce back this year, and Gilead Sciences could be a key beneficiary, according to Bank of America. Analyst Geoff Meacham upgraded Gilead to buy from neutral. He increased his target price for the stock by $7 to $95, which suggests shares stand to gain 28.5% from where they closed Thursday. Shares of California-based Gilead have dropped 13.9% so far this year. "With the potential for broader interest in the sector, we are more optimistic on performance into 2H23," Meacham said.

Persons: Geoff Meacham, Meacham, biopharma, — Michael Bloom Organizations: Gilead Sciences, Bank of America, PrEP, Kite Pharma Locations: Gilead, California, HCV

☆ This little-known biotech stock has 'blockbuster potential,' says Citi
▼ + stars: | 2023-09-05 | by ( Hakyung Kim | ) www.cnbc.com time to read: +2 min

Autoimmune disease drugmaker Cabaletta Bio could soon have a multibillion-dollar product on its hands, according to Citi. Analyst Samantha Semenkow initiated research coverage with a buy rating on Cabaletta shares. Last October, the biotech firm obtained an exclusive, worldwide license for its autoimmune disease therapy CABA-201. The treatment is a CD19-directed chimeric antigen receptor modified T-cell therapy (CART), a treatment for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. "In our view, the risk/reward is favorable into initial CABA-201 clinical data in 1H24."

Persons: Samantha Semenkow, Semenkow, Cabaletta, Morgan Stanley, Cowen, — CNBC's Michael Bloom Organizations: Citi, Evercore ISI Locations: 1H24

☆ Bayer says Parkinson's stem cell therapy improves symptoms in initial trial
▼ + stars: | 2023-08-28 | by ( Ludwig Burger | ) www.reuters.com time to read: +3 min

FRANKFURT, Aug 28 (Reuters) - Bayer (BAYGn.DE) said an experimental stem cell therapy developed by its U.S. subsidiary BlueRock had shown signs of easing Parkinson’s disease symptoms in an early 12-patient trial. The German drugmaker announced the trial had succeeded in a brief summary in June, saying it was a first for a stem-cell Parkinson's therapy, but held back details for a medical conference. The five participants on a lower dose experienced 0.72 hours longer per day with well-controlled symptoms on average and the time of worsening symptoms was 0.75 hours shorter per day for them. For BlueRock's experimental therapy, the researchers took human pluripotent embryonic stem cells and transformed them into dopamine-producing nerve cells. Parkinson's, for which there is no cure and which affects more than 10 million people worldwide, causes progressive brain damage.

Persons: BlueRock, Christian Rommel, Bayer's, Britain's, Ludwig Burger, Susan Fenton Organizations: FRANKFURT, Bayer, U.S, drugmaker, International Congress, Cambridge University, South Korea's, CHA Hospital, Cyto Therapeutics, Chinese Academy of Sciences, Harvard University, Japan's Kyoto University Hospital, Thomson Locations: Copenhagen, Denmark, Australia, United States

☆ UBS says this stock is the 'best story' among U.S. large caps, sees more than 15% upside ahead
▼ + stars: | 2023-08-14 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +3 min

Calling it the "best fundamental story" among U.S. large caps, UBS analyst Colin Bristow on Friday lifted his price target to $612 from $526. The stock has already gained 47% year to date, mostly on the back of lofty expectations for weight loss drug sales. Bristow also expects data for its Crohn's disease treatment by year-end, as well as readouts on Verzenio for prostate cancer. Then by 2024, Lilly is expected to submit data for a cell therapy for type 1 diabetes. And there's potential for even more upside if the drug adds other indications such as renal treatment, he said.

Persons: Eli Lilly, Colin Bristow, Bristow, Lilly, Jaypirca, Novo's, — CNBC's Michael Bloom Organizations: UBS, Food, Drug, European Union, Novo Locations: U.S

☆ Insight: What happens when a $2 million gene therapy is not enough
▼ + stars: | 2023-08-12 | by ( Deena Beasley | ) www.reuters.com time to read: +13 min

Their experience raises broader questions around other high-cost gene therapies coming to market, sometimes after accelerated regulatory approvals, drug pricing experts said. Gene therapies work by replacing genes – the body's blueprint for its development. The gene Zolgensma delivers instructs the body to make a protein vital for muscle control. If gene therapies do fall short, it becomes harder to justify prices that researchers have argued are already poor value. More recently, the first hemophilia gene therapy approved by the U.S. Food and Drug Administration was priced by CSL Behring at $3.5 million; 26 more gene therapies are in late-stage development, according to IQVIA.

Persons: Elizabeth Kutschke, Ben, Zolgensma, Ben Kutschke, neurologists, Sitra Tauscher, Wisniewski, Ben's, Roger Hajjar, Brigham Gene, Kutschke, Vasant Narasimhan, Stacie Dusetzina, Roche's, Biogen, Roche, Maha Radhakrishnan, Steven Pearson, It's, Sree Chaguturu, Amanda Cook, Weston, Jackson, Cook, Elizabeth, Jerry Mendell, Russell Butterfield, –, Biogen's, Mendell, UMR, Spinraza, Eric Cox, Caroline Humer, Sara Ledwith Organizations: Reuters, U.S, Novartis, IQVIA Institute, Human Data, Novartis Gene Therapies, Mass, Cell Therapy, U.S . Food, Drug Administration, CSL Behring, CSL, Nashville's Vanderbilt University School of Medicine, Clinical, Economic, CVS Health, Aetna, SMA, Nationwide Children's Hospital, University of Utah Health, Children's, UnitedHealth, Thomson Locations: Oak Park, Berwyn , Illinois, Swiss, U.S, Lebanon , Virginia, United States, Columbus , Ohio, Russia, Kazakhstan, Chicago

Search resuls for: "Cell Therapy"

25 mentions found